Chemical Constituents of the New Endophytic Fungus

*Mycosphaerella* sp. nov. and Their Anti-Parasitic Activity

Eufemio Moreno\(^a\), Titto Varughese\(^{a,b}\), Carmenza Spadafora\(^c\), A. Elizabeth Arnold\(^d\), Phyllis D. Coley\(^e\), Thomas A. Kursar\(^e\), William H. Gerwick\(^f\), and Luis Cubilla-Rios\(^{a,*}\)

\(^a\)Laboratory of Tropical Bioorganic Chemistry, Faculty of Natural Exact Sciences and Technology, University of Panama, Republic of Panama

\(^b\)Smithsonian Tropical Research Institute, Unit 0948, APO AA 34002-0948

\(^c\)Institute for Advanced Scientific Investigation and High Technology Services, National Secretariat of Science, Technology, and Innovation, City of Knowledge, Republic of Panama

\(^d\)School of Plant Sciences, The University of Arizona, Tucson, AZ 85721 USA

\(^e\)Department of Biology, University of Utah, Salt Lake City, Utah

\(^f\)Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093

Abstract

Chemical investigation of a new endophytic fungus, *Mycosphaerella* sp. nov. strain F2140 associated with the foliage of the plant *Psychotria horizontalis* (Rubiaceae) in Panama, resulted in the isolation of cercosporin (1) and a new cercosporin analogue (3) as the major components. The structures of minor compounds in the extract were elucidated by detailed spectroscopic analysis as \(2-(2\text{-butyl})-3\text{-hydroxy-6-ethyl-6-methylcyclohex-2-ene-1,5-dione (4)}\), \(3-(2\text{-butyl})-6\text{-ethyl-6-methyl-5-hydroxy-2-methoxy-cyclohex-2-eneone (5)}\), and an isomer of \(5 (6)\). To study the influence of the hydroxy groups on the anti-parasitic activity of cercosporin, compound 1 was acetylated to obtain derivative 2. The isolated compounds 1–6 were tested *in vitro* to determine their anti-parasitic activity against the causal agents of malaria (*Plasmodium falciparum*), leishmaniasis (*Leishmania donovani*), and Chagas disease (*Trypanosoma cruzi*). Also, the cytotoxicity and potential anticancer activity of these compounds were evaluated using mammalian Vero cells and MCF7 cancer cell lines, respectively. Compounds 1 and 2 displayed high potency against *L. donovani* (IC\(_{50}\) 0.46 and 0.64 \(\mu\)M), *T. cruzi* (IC\(_{50}\) 1.08 and 0.78 \(\mu\)M), *P. falciparum* (IC\(_{50}\) 1.03 and 2.99 \(\mu\)M), and MCF7 cancer cell lines (IC\(_{50}\) 4.68 and 3.56 \(\mu\)M). Compounds 3–6 were not active in these assays at a concentration of 10 \(\mu\)g/mL.

Keywords

Endophytic fungus; *Mycosphaerella* sp. nov; Cercosporin; Anti-parasitic activity

As part of a continuing program to identify novel compounds for the treatment of parasitic diseases, the Panamanian International Cooperative Biodiversity Group (ICBG) [1a, 1b] has been investigating new anti-parasitic agents from plants [1c, 1d], marine organisms [1e, 1f], and more recently, endophytic fungi [1g, 1h]. In the course of these latter studies, 21 fungal...
strains were isolated from the leaves of a neotropical shrub, *Psychotria horizontalis* (Rubiaceae). The extract from a new fungal species, identified as *Mycosphaerella* sp. nov., was selected for further purification based on initial bioactivity results. Herein, we report the isolation and structural elucidation of a new cercosporin analogue (3) along with cercosporin (1) as major metabolites, together with four new minor metabolites, 2-(2-butyl)-3-hydroxy-6-ethyl-6-methylcyclohex-2-ene-1, 5-dione (4), 3-(2-butyl)-6-ethyl-6-methyl-5-hydroxy-2-methoxy-cyclohex-2-eneone (5), and its isomer 6. The compounds were evaluated for anti-parasitic and cytotoxic activities. Although cercosporin is a well-known phytotoxin with significant cytotoxic activity, its potential anti-parasitic activities have not been previously reported.

Extracts from all the tested growth media were found to be active against *T. cruzi* (IG, 86–94%), *P. falciparum* (IG, 90–99%), and *L. donovani* (IG, 90.8–99.1%) (Table 1). The similar, non-selective bioactivity profile of all extracts from F2140 strain led us to the conclusion that a major compound present in all the extracts likely was responsible for the activity.

TLC of extracts showed a dark brownish spot corresponding to a molecular weight of 535 amu following analysis by low resolution mass spectrometry. In addition, the MS data of the mycelial extract from potato dextrose culture showed an additional peak at 537 amu, and thus was probable an analogue of the major compound. Based on these results, the mycelial extract of potato dextrose culture was selected for further purification.

Cercosporin (1), the major component of the crude extract, was identified by comparison of its NMR and MS data with those reported previously [2a, 2b]. Acetylation of cercosporin gave a tetra-acetate (2; Fig. 1), which showed physicochemical properties consistent with the literature data [2c, 2d].

The molecular formula of compound 3 was established as C_{29}H_{28}O_{10} on the basis of its APCI-HR-MS (*m/z* 537.1758 [M + H]^+). The ^1^H and ^13^C NMR signals of 3 were closely similar to those of 1. However, 3 displayed twice the number of NMR signals, suggesting the lack of structural symmetry in 3. Also, the NMR signals corresponding to the methylene group [δ_{H} 5.75 (2H, s, H-21); δ_{C} 92.6] of the dioxepane ring in compound 1 was replaced by the signals for a methoxy group [δ_{H} 4.27 (3H, s, OMe); δ_{C} 57.9] in compound 3, indicating a ring-opened analogue of cercosporin with a methoxy group at one terminus and a hydroxy group at the other. The position of the methoxy group in 3 was confirmed by HMBC correlations from δ_{H} 4.27 to δ_{C} 163.3 (C-12).

Compound 4 was obtained as colorless oil with a specific rotation ([α]_{26}^D) of −2.6°. The molecular formula was determined to be C_{13}H_{29}O_{3} based on the APCI-HR-MS data [M + H]^+ at *m/z* 225.1471. The ^13^C spectrum of 4 confirmed the presence of 13 carbon resonances, with their multiplicities determined from a DEPT spectrum as four methyl [δ_{C} 9.2, 12.5, 18.3, and 18.8], three methylene [δ_{C} 27.4, 28.1, and 55.9], one methine [δ_{C} 33.1] and five quaternary carbons [δ_{C} 50.4, 152.7, 161.6, 207.4, and 209.5]. The HSQC spectrum identified the corresponding ^1^H signals for methyl [δ_{H} 0.71 (t, J = 7.5 Hz, H-2′)], 0.84 (t, J = 7.5 Hz, H-4′), 1.26 (d, J = 7.2 Hz, H-1′), and 1.11 (s, H-1‴) groups. Analysis of the COSY spectrum suggested the presence of ethyl and 2-butanol moieties. In the HMBC spectrum, H-2′ [δ_{H} 2.85] of the sec-butyl group showed long-range correlations to C-1 [δ_{C} 207.4], C-2 [δ_{C} 161.6] and C-3 [δ_{C} 152.7] indicating that the 2-butyl group was attached to a double bond (C-2, see Figure 3). HMBC correlations from the methyl group [δ_{H} 1.11 to C-1 ″ [δ_{C} 28.0], C-6 [δ_{C} 50.4], C-1 [δ_{C} 207.4], and C-5 [δ_{C} 209.5] confirmed that the methyl and ethyl groups were attached to C-6. Finally, the
HMC correlations of H-4 with C-3, C-2 and C-5 enabled formulation of a six-membered cyclic diketoenol structure for 4. The absolute configuration of C-6 position was not determined due to the low amount of compound isolated. Thus, the structure of 4 was determined to be 2-(2-butyl)-3-hydroxy-6-ethyl-6-methylocyclohex-2-ene-1,5-dione- (4).

Compound 5 was obtained as colorless oil with a specific rotation ([α] 26 D) of +60.2. The molecular formula was determined as C14H24O3 by APCI-HR-MS in positive ion mode, displaying a protonated molecular ion peak at m/z 241.1786 [M+H]⁺. The formula was consistent with the number of protons and carbons observed in the NMR spectra. In addition to a methoxy functional group [δH 3.60 (s, OMe), δC 59.9], a methyl [δH 1.14 (s, H-1‴), δC 17.7], an ethyl [δH 0.84 (t, J = 7.5 Hz, H-2‴), δC 7.9; δH 1.64 (t, J = 7.5 Hz, H-1″″), δC 22.7] and a 2-butyl [δH 1.04 (d, J = 7.0 Hz, H-1″″), δC 18.6; δH 3.00 (m, H-2′′), δC 34.8; δH 1.41 (m, H-3″″), δC 27.1; δH 0.88 (t, J = 7.5 Hz, H-4″″), δC 12.5] group were identified from the NMR data. The remaining six 13C NMR signals [δC 198.0 (C-1), 147.3 (C-2), 146.3 (C-3), 73.1 (C-5), 50.9 (C-6) and 28.8 (C-4)] belonged to a cyclic skeleton similar to 4. The positions of the functional groups in 5 were confirmed by analysis of HMBC correlations from methylene [δH 2.48, H-4] methyl [δH 1.14 H-1‴″″], and methoxy [δH 3.60, OMe] protons. The sec-butyl group was now attached to C-3 as indicated by the correlation of H-2′″ with C-2 and C-3, and H2-4 with C-2′″, C-2, C-3 and C-5. The position of the OMe was determined by the correlation of this three proton resonance with C-2 (see Figure 2). Thus, the structure of 5 was determined to be 3-(2-butyl)-6-ethyl-6-methyl-5-hydroxy-2-methoxy-cyclohex-2-eneone.

Compound 6 was obtained as a colorless oil with a specific rotation ([α] 26 D) of +15.7. Its molecular formula was determined as C14H24O3 based on the mass spectrum (APCI-HR-MS) displaying an [M+H]⁺ at m/z 241.1757. Compound 6 showed very similar NMR signals to 5 and these were confirmed by further 2D NMR analysis. On the basis of these data, compound 6 was identified as a diastereomer of 3-(2-butyl)-6-ethyl-6-methyl-5-hydroxy-2-methoxy-cyclohex-2-eneone.

Cercosporin belongs to the perylenequinone-class of metabolites [3] which are of polyketide origin [4] and are produced by fungi within the genus Cercospora [2b]. It is a photosensitizing toxin that produces highly reactive superoxide anions as well as singlet oxygen upon irradiation. This causes peroxidation of membrane fatty acids, leading to rupture of plasma membrane in plants and cell death [5].

Cercosporin is highly active against P. falciparum (IC50 1.03 μM), L. donovani (IC50 0.46 μM), and T. cruzi (IC50 1.08 μM). This bioactivity profile of cercosporin showed that it was...
not selective between the assayed parasites. Except in *T. cruzi* assay (Table 1), the acetylated cercosporin showed lower activity compared to the parent compound. However, the bioactivity of cercosporin varied only slightly when it was acetylated. It is possible that the hydroxy groups do not have a marked effect on the bioactivity of cercosporin, or that the esters are labile and removed by esterases upon entering cells. Because the bioassays were performed in the dark, any possible phototoxic effect of cercosporin on the parasites was minimized. Compound 1 and 2 showed lower cytotoxicity to mammalian Vero cells (1.54 and 1.24 μM) compared to their anti-leishmanial activity, thus giving a modest therapeutic window of 3.4 and 1.9, respectively (Table 1). Compound 3, identified as a seven-membered dioxepane ring-opened analogue of cercosporin, showed a significant reduction in activity in all of these biological assays (IC$_{50}$>10 μg/mL), indicating the importance of the methenedioxy functionality to the biological properties of compound 1. A similar reduction activity was also observed with some of the anti-leishmanial alkaloids isolated in our lab [9]. The minor compounds 4–6 did not show significant activity (IC$_{50}$>10 μg/mL) in any of the biological assays.

Overall, the results presented here suggest that cercosporin produced by the new fungal strain *Mycosphaerella* sp. nov is responsible for the antiparasitic and cytotoxic activities. The results also provide further insights into the structure-activity relationship of cercosporin against the tropical parasites which could be useful in designing more potent and selective agents against these diseases.

**Experimental**

**Isolation and identification of fungal strain**

The host plant *P. horizontalis* was collected from the tropical forest at Barro Colorado Natural Monument, Panama and was identified by Dr. Alicia Ibáñez, a voucher specimen (B1704) was deposited at the Smithsonian Tropical Research Institute, Panama. The fungal strain was isolated on malt extract agar from a surface-sterilized, healthy, mature leaf in August 2005 following methods outlined in Arnold and Lutzoni [10]. Because the strain did not sporulate in culture, phylogenetic analyses of molecular sequence data were used to verify its taxonomic placement.

Briefly, total genomic DNA was extracted from fresh mycelium following Arnold and Lutzoni [10]. The nuclear ribosomal internal transcribed spacers and 5.8s gene (nrITS) were amplified as a single fragment and sequenced bidirectionally at the Genomics and Technology Core at The University of Arizona using primers ITS1F and ITS4 [11] (for PCR protocols see Hoffman and Arnold [12] and Higgins *et al.* [13]). Forward and reverse reads were assembled and evaluated by *phred* and *phrap* [14a,14b] with automation provided by Mesquite, http://mesquiteproject.org., and manual editing in Sequencher v4.5 (Gene Codes Corporation, Ann Arbor, MI). The consensus sequence was submitted to a BLAST search of the NCBI GenBank database for preliminary identification at higher taxonomic levels and to establish appropriate tax sampling for phylogenetic analysis. BLAST matches suggested placement in *Mycosphaerella* (Mycosphaerellaceae, Capnodiales, Dothideomycetes, and Ascomycota). To overcome widely recognized limitations associated with BLAST-based taxonomy, including potential misidentification of sequences, relatively limited representations of endophytic fungi, and the uncertain validity of taxonomic placement based on the non-evolutionary BLAST algorithm, were verified placement using phylogenetic analyses. Briefly, maximum likelihood analyses of two complementary data sets, the first consisting of 100 sequences of top hits obtained from GenBank, and the second consisting of 34 sequences of closely related strains and eight strains obtained in broader surveys of endophyte diversity [7a,7b] confirmed placement in *Mycosphaerella* and provided high bootstrap support for recognition of this strain as a novel species relative to
known diversity in this highly species-rich, and often geographically specialized, genus. Therefore, the strain was characterized as a new species of Mycosphaerella (Mycosphaerella sp. nov., Arnold et al. unpub.) [7c]. A voucher specimen was deposited as plugs of agar in sterile water at the Smithsonian Tropical Research Institute, Panama (accession F2140), and at the Robert L. Gilbertson Mycological Herbarium, The University of Arizona (accession F2140/TK1648).

**Cultivation and extraction procedures**

F2140 was cultured on slants of potato dextrose agar (PDA) at 25°C for 7 days. Agar plugs (2x2 cm) then were transferred to four different media (700 mL each; malt extract, potato dextrose, Czapek Dox, and V8) and incubated at 28°C for 15 d on a rotary shaker (120 rpm). Suspensions from each medium were vacuum-filtered and the filtrate successively partitioned between hexane, chloroform, and ethyl acetate to obtain 29.6, 32.1, 37.4 mg (malt extract), 54.4, 129.4, 67.0 mg (potato dextrose), 5.9, 34.7, 28.3 mg (Czapek Dox) and 10.3, 9.4, 8.1 mg (V8) of extract, respectively. Erlenmeyer flasks containing each medium without inocula were treated in the same way as controls. Mycelial mass collected by filtration from each medium was homogenized using a polytron and extracted with EtOAc to produce 149.7, 1511.5, 226.1, and 81.1 mg of extract from each medium, respectively. A total of 16 extracts, obtained as described above, were evaluated for their anti-parasitic activity at a concentration of 10 μg/mL.

**Isolation of compounds**

Mycelial extract from potato dextrose (100 mg from 1.5 g) was chromatographed on a GRACE Econosphere NP-HPLC column (250 x 10 mm) using CHCl3-MeOH (97:3) as eluents for 40 min at a flow rate of 1.5 mL/min to yield two major compounds: cercosporin (1) (47 mg, tR 17.2 min), and a new isomer of cercosporin (3) (20 mg, tR 21.3 min). Following Kuyama et al. [2c], 10 mg of cercosporin was acetylated in pyridine using acetic anhydride to obtain a tetra-acetyl derivative. The remainder of the extract (1.4 g) was fractionated over a silica column (70–230 mesh, Merck) using hexanes-CHCl3, CHCl3-MeOH mixtures and MeOH as eluents to give three subfractions (A-C). Subfraction A (20 mg) was further purified on an Xterra C18 HPLC column (250 x 10 mm) using 35% aqueous MeCN for 60 min at a flow rate of 1.5 mL/min to obtain a mixture (5.6 mg, tR 44.6 min) and the new compound (4) (2.0 mg, tR 46.7 min). The mixture of compounds was successfully separated using a normal phase HPLC column chromatography (GRACE Econosphere, 250 x 10 mm) using an isocratic solvent system containing hexanes-CHCl3 (4:6) for 30 min at a flow rate of 1.0 mL/min to give two new compounds (5) (2.0 mg, tR 46.7 min), and (6) (0.9 mg, tR 52.5 min), respectively.

**General experimental procedures**

Optical rotations were measured with a Rudolf Research Analytical Autopol III 6971 automatic polarimeter. NMR spectra were recorded on a Bruker spectrometer with standard pulse sequences operating at 300 MHz in 1H NMR and 75 MHz in 13C NMR using TMS as an internal chemical shift reference. Mass spectra were acquired on a JEOL LC-mate mass spectrometer. TLC was performed on precoated silica gel plates (Kieselgel 60, F254, 20 x 20 cm, 0.25 mm thick, Merck). Spots were detected by staining with a solution of p-anisaldehyde-sulfuric acid in methanol followed by heating. Reverse phase HPLC was performed on a Waters 600 model system with a photodiode array UV detector 2996. Normal phase HPLC was performed on a Waters 1515 model system with a dual wavelength UV detector model 2487.
Bioassays

Leishmania bioassay

Axenically grown (cell free) amastigotes of *L. donovani* (LD-1S/MHOM/SD/00-strain 1S), the species responsible for the visceral and lethal forms of leishmaniasis, were used to assess parasite growth and survival. Samples were tested in duplicate at 10 μg/mL. The results were expressed as a percentage of growth inhibition (IG) compared to controls. Samples that showed above 70% IG were considered active and were then assayed at four different concentrations (0.08, 0.4, 2, and 10 μg/mL) to determine IC50 values. Amphotericin B was used as a positive control with the typical IC50 response of 0.08–0.13 μM [1h,15].

Chagas’ disease bioassays

*T. cruzi* bioassays were performed using a colorimetric method, and the inhibition of parasite growth was assessed by the expression of the reporter gene for beta-galactosidase (β-Gal) in the recombinant Tulahuen clone C4 of *T. cruzi*. Assays were performed in duplicate on the amastigote, the intracellular form of the parasite infecting African green monkey kidney (Vero) cells, exposed during 120 h to different concentrations (10, 2 and 0.4 μg/mL) of the test compounds at 37°C under an atmosphere of 5% CO2/95% air. The resulting color from the cleavage of chlorophenol red-β-D-galactoside (CPRG) by β-Gal expressed by the parasite was measured at 570 nm. The concentration that inhibited 50% expression of β-Gal (IC50) was calculated by log regression of the obtained optical density values, and compared with the untreated controls. Nifurtimox was used as a positive control (IC50 10–16 μM) [16,17].

Malaria bioassays

Antiplasmodial activity was evaluated using a fluorometric method based on the detection of parasite DNA with the fluorochrome PicoGreen using a chloroquine-resistant strain (Indochina W2) of *P. falciparum*. The sample was considered active if it inhibited >70% of the growth of the parasites as compared to their untreated controls at 10 μg/ml. The IC50 was calculated by normal regression of the resulting inhibition percentages at 0.08, 0.4, 2, and 10 μg/mL. The parasites were maintained in vitro by a modification of the method of Trager and Jensen [18a]. Chloroquine was used as a positive control (IC50 80–100 nM) [1g, 18b].

Cancer bioassays

Cytotoxic activity against MCF-7 human breast cancer cells was performed following the standard protocol of the National Cancer Institute [19]. Adriamycin was used as a positive control (IC50 0.02–0.3 nM).

Mammalian Cell Cytotoxicity bioassay

Vero cells, derived from kidneys of the African green monkey, were adhered to 96-well plates and examined for reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO). After treatment with the test compound for 4 h of incubation at 37°C, cell viability was evaluated in an ELISA reader at 570 nm [1g,17, and 20].

Compound 3

Dark red powder.

[α]D26: −879 (c 0.045, CHCl3).
HNMR (300 MHz, CDCl3): δ 0.61 (d, J = 6.2 Hz, 3H, H-3′′), 0.65 (d, J = 6.2 Hz, 3H, H-3″), 2.79 (dd, J = 12.7, 6.0 Hz, 1H, H-1a″), 2.85 (dd, J = 12.7, 6.0 Hz, 1H, H-1a′), 3.40 (m, 1H, H-2″), 3.43 (m, 1H, H-2′), 3.51 (dd, J = 12.7, 1.9 Hz, 1H, H-1b″), 3.53 (dd, J = 12.7, 2.7 Hz, 1H, H-1b′), 4.19 (s, 3H, H-23), 4.20 (s, 3H, H-22), 4.27 (s, 3H, H-21), 6.86 (s, 1H, H-13), 6.91 (s, 1H, H-3).

CNMR (75 MHz, CDCl3): δ 23.6 (C-3″), 23.8 (C-3′), 42.2 (C-1″), 42.4 (C-1′), 58.1 (C-21), 61.6 (C-22, C-23), 68.5 (C-2′, C-2″), 101.9 (C-3), 106.3 (C-10), 107.1 (C-20), 107.9 (C-13), 112.7 (C-1), 113.5 (C-11), 128.2 (C-9), 129.5 (C-19), 131.6 (C-17/7), 134.5 (C-8), 136.2 (C-18), 152.9 (C-6), 153.2 (C-2), 163.3 (C-2), 169.5 (C-4), 170.0 (C-14), 180.5 (C-5), 181.8 (C-15). APCI-HR-MS m/z 537.1758 [M+H]+ (calcd for C29H29O10, 537.1761).

2-(2-butyl)-6-ethyl-3-hydroxy-6-methylcyclohex-2-ene-1,5-dione (4)—Colorless oil.
[a]D26: −2.6 (c 0.07, CHCl3).

HNMR (300 MHz, CDCl3): δ 0.71 (t, J = 7.4 Hz, 3H, H-2″), 0.84 (t, J = 7.4 Hz, 3H, H-4′), 1.11 (s, 3H, H-1‴), 1.26 (d, J = 7.1 Hz, 3H, H-1′), 1.69 (m, 2H, H-1″), 1.71 (m, 2H, H-3′), 2.85 (m, 1H, H-2′), 4.64 (s, 2H, H-4).

CNMR (75 MHz, CDCl3): δ 9.2 (C-2″), 12.5 (C-4′), 18.3 (C-1‴), 18.8 (C-1′), 27.4 (C-3′), 28.1 (C-1″), 33.1 (C-2′), 50.4 (C-6), 55.9 (C-4), 152.7 (C-3), 161.6 (C-2), 207.4 (C-1), 209.5 (C-5).

APCI-HR-MS m/z 225.1471 [M+H]+ (calcd for C13H21O3, 225.1491);

3-(2-butyl)-6-ethyl-5-hydroxy-2-methoxy-6-methyl-cyclohex-2-enone (5)—Colorless oil.
[a]D26: +60.2 (c 0.04, CHCl3).

HNMR (300 MHz, CDCl3): δ 0.84 (t, J = 7.7 Hz, 3H, H-2″), 0.88 (t, J = 7.4 Hz, 3H, H-4′), 1.11 (s, 3H, H-1″), 1.26 (d, J = 7.1 Hz, 3H, H-1′), 1.69 (m, 2H, H-1″), 1.71 (m, 2H, H-3′), 2.85 (m, 1H, H-2′), 4.64 (s, 2H, H-4).

CNMR (75 MHz, CDCl3): δ 7.9 (C-2″), 12.5 (C-4′), 18.3 (C-1″), 18.8 (C-1′), 27.4 (C-3′), 33.1 (C-2′), 50.4 (C-6), 59.9 (OMe), 73.1 (C-5), 146.3 (C-3), 147.3 (C-2), 198.0 (C-1).

APCI-HR-MS m/z 241.1786 [M+H]+ (calcd for C14H25O3, 241.1804);

Compound 6

Colorless oil.
[a]D26: +15.7 (c 0.07, CHCl3).

HNMR (300 MHz, CDCl3): δ 0.84 (t, J = 7.3 Hz, 3H, H-2″), 0.88 (t, J = 7.3 Hz, 3H, H-4′), 1.05 (d, J = 7.0 Hz, 3H, H-1″), 1.14 (s, 3H, H-1‴), 1.41 (m, 2H, H-3′), 1.65 (m, 2H, H-1′), 2.35 (dd, J = 18.2, 7.6 Hz, 1H, H-4a), 2.45 (dd, J = 18.2, 5.1 Hz, 1H, H-4b), 3.01 (m, 1H, H-2′), 3.60 (s, 3H, OMe), 3.89 (t, J = 5.4 Hz, 1H, H-5).

CNMR (75 MHz, CDCl3): δ 6.8 (C-2″), 11.3 (C-4′), 16.9 (C-1″), 17.3 (C-1′), 21.7 (C-1″), 26.4 (C-3′), 27.9 (C-4), 33.6
(C-2'), 49.6 (C-6), 58.9 (OMe), 71.9 (C-5), 144.9 (C-3), 146.2 (C-2), 197.1 (C-1). APCI - HR-MS m/z 241.1757 [M+H]+ 241.1804).

Acknowledgments

This work was supported by US NIH grant for the International Cooperative Biodiversity Groups program (ICBG–Panama; 2 U01 TW006634-06). We thank Malkanthi Gunatilaka and Douglas Mahana for assistance with DNA sequencing, and the College of Agriculture and Life Sciences at the University of Arizona for logistical and financial support. We express our thanks to the personnel of Panama’s Autoridad Nacional del Ambiente for facilitating this research.

References


Figure 1.
Chemical Structures of the Isolated Metabolites (1, 3–5) and one Derivative (2).
Figure 2.
Key HMBC correlations for placing substituents on compounds 4 and 5
### Table 1

Biological Activity [IC$_{50}$, μM] * of Compounds 1 and 2 to Tropical Parasites and MCF-7 Cell Lines

<table>
<thead>
<tr>
<th></th>
<th>L. donovani</th>
<th>P. falciparum</th>
<th>T. cruzi</th>
<th>MCF-7</th>
<th>Vero cells</th>
<th>TW</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound 1</td>
<td>0.46 ± 0.05</td>
<td>1.03 ± 0.03</td>
<td>1.08 ± 0.03</td>
<td>4.68 ± 0.20</td>
<td>1.54 ± 0.10</td>
<td>3.4</td>
</tr>
<tr>
<td>Compound 2</td>
<td>0.64 ± 0.05</td>
<td>2.99 ± 0.40</td>
<td>0.78 ± 0.07</td>
<td>3.56 ± 0.20</td>
<td>1.24 ± 0.10</td>
<td>1.9</td>
</tr>
</tbody>
</table>

*The experiments were performed in duplicate. Results indicate mean ± standard error. TW, therapeutic window.